Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.

"Conflict-of-interest disclosure: N.M.-C. received honoraria from Janssen; received travel support and honoraria from and served on the advisory board of AbbVie; received travel support and honoraria from AstraZeneca; and served on the advisory board of and received honoraria from Takeda. C.P.F. consults and performs educational activities for AbbVie, AstraZeneca, Atara Biotherapeutics, Celgene/Bristol Myers Squibb, Genmab, Gilead/Kite, Incyte, Janssen, Lilly, MorphoSys, Ono, Roche, and Takeda, and received research funding from 10.13039/100017239BeiGene. A.D. serves on the advisory board of and received research funding, honoraria, and travel fees for scientific conferences from 10.13039/100006436Celgene and Roche; serves on the advisory board of and received research support and honoraria from Kite; serves on the advisory board of and received research support from Karyopharm Therapeutics; received research support and honoraria from Acerta Pharma/AstraZeneca and ADC Therapeutics; serves on the advisory board of Incyte; received research support from Merck Sharp & Dohme (MSD); and serves on the advisory board of AbbVie. T.A.E. reports education and advisory board honoraria, and scientific conference travel support from Roche; reports honoraria and research and scientific conference travel support from Gilead; reports education and advisory board honoraria from Kite; reports honoraria from Janssen; reports honoraria and scientific conference travel support from AbbVie; received honoraria, research funding, and scientific conference travel support from AstraZeneca; received advisory board honoraria from, and served on the steering committee of, Loxo Oncology; received advisory board honoraria and research funding from BeiGene; and received advisory board honoraria from Incyte and Secura Bio. W.O. reports speaker honoraria from Roche, Takeda, Pfizer, Kite Gilead, AstraZeneca, Novartis, Kyowa Kirin, Incyte, and Janssen; serving on advisory boards for Roche, Servier, Takeda, MSD, Kite Gilead, Novartis, Beigine, Autolus, Kyowa Kirin, Incyte, Sobi, Janssen, and Synoes; and support for medical education from Novartis, Takeda, and Roche. W.T. has received honoraria, speaker's fees, and travel support to international conferences from Roche, Takeda, Incyte, and Gilead. The remaining authors declare no competing financial interests."

"10.13039/100017239BeiGene; 10.13039/100006436Celgene"